Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anjali Owens

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
Annals of Internal Medicine|April 30, 2019
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical TrialStephen B Heitner, Daniel Jacoby, Steven J Lester, et al.
Heart Rhythm|November 29, 2024
Managing drug-drug interactions with mavacamten: A focus on combined use of antiarrhythmic drugs and anticoagulantsFabrizio Ricci, Lorenzo V Molinari, Davide Mansour, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 19, 2022
TTR variants in patients with dilated cardiomyopathy: An investigation of the DCM Precision Medicine StudyBarry H Trachtenberg, Javier Jimenez, Alanna A Morris, et al.
American Journal of Medical Genetics. Part A|May 2, 2022
MYH7 variants cause complex congenital heart diseaseAlyssa Ritter, Jacqueline Leonard, Christopher Gray, et al.
The American Journal of Cardiology|April 24, 2025
Prognostic Value of Compact Myocardial Thinning in Patients with Left Ventricular NoncompactionTea Gegenava, Martijn Tukker, Kadir Caliskan, et al.
JACC. Heart Failure|September 25, 2025
Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic CardiomyopathyMilind Y Desai, Niccolo Maurizi, Elena Biagini, et al.
ESC Heart Failure|August 15, 2024
Characterization and natural history of patients with LMNA-related dilated cardiomyopathy in the phase 3 REALM-DCM trialPablo Garcia-Pavia, Neal K Lakdawala, Gianfranco Sinagra, et al.
American Heart Journal|May 26, 2021
Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapyMilind Y Desai, Kathy Wolski, Anjali Owens, et al.
Heart Rhythm|February 22, 2020
Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter studyBabak Nazer, Zack Dale, Gianmarco Carrassa, et al.
JAMA Cardiology|November 16, 2022
Knowledge of Genome Sequencing and Trust in Medical Researchers Among Patients of Different Racial and Ethnic Groups With Idiopathic Dilated CardiomyopathyHanyu Ni, Elizabeth Jordan, Jinwen Cao, et al.
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Annals of Internal Medicine|April 30, 2019
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical TrialStephen B Heitner, Daniel Jacoby, Steven J Lester, et al.
Heart Rhythm|November 29, 2024
Managing drug-drug interactions with mavacamten: A focus on combined use of antiarrhythmic drugs and anticoagulantsFabrizio Ricci, Lorenzo V Molinari, Davide Mansour, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 19, 2022
TTR variants in patients with dilated cardiomyopathy: An investigation of the DCM Precision Medicine StudyBarry H Trachtenberg, Javier Jimenez, Alanna A Morris, et al.
American Journal of Medical Genetics. Part A|May 2, 2022
MYH7 variants cause complex congenital heart diseaseAlyssa Ritter, Jacqueline Leonard, Christopher Gray, et al.
The American Journal of Cardiology|April 24, 2025
Prognostic Value of Compact Myocardial Thinning in Patients with Left Ventricular NoncompactionTea Gegenava, Martijn Tukker, Kadir Caliskan, et al.
JACC. Heart Failure|September 25, 2025
Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic CardiomyopathyMilind Y Desai, Niccolo Maurizi, Elena Biagini, et al.
ESC Heart Failure|August 15, 2024
Characterization and natural history of patients with LMNA-related dilated cardiomyopathy in the phase 3 REALM-DCM trialPablo Garcia-Pavia, Neal K Lakdawala, Gianfranco Sinagra, et al.
American Heart Journal|May 26, 2021
Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapyMilind Y Desai, Kathy Wolski, Anjali Owens, et al.
Heart Rhythm|February 22, 2020
Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter studyBabak Nazer, Zack Dale, Gianmarco Carrassa, et al.
JAMA Cardiology|November 16, 2022
Knowledge of Genome Sequencing and Trust in Medical Researchers Among Patients of Different Racial and Ethnic Groups With Idiopathic Dilated CardiomyopathyHanyu Ni, Elizabeth Jordan, Jinwen Cao, et al.
Pageof 7